Mark Raffeld
0000-0002-4039-6957
2 papers found
Refreshing results…
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma
Missing publications? Search for publications with a matching author name.